Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia

American Journal of Pathology

Volumn 161, Issue 4, 2002, Pages 1357-1369

  Lee, Hyangkyu ^a   Park, David S ^a   Razani, Babak ^a   Russell, Robert G ^a   Pestell, Richard G ^a   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; OLIGOMER; STRUCTURAL PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOCATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE TARGETING; GOLGI COMPLEX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; TUMOR SUPPRESSOR GENE;

EID: 0036791604     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64412-4     Document Type: Article

References (72)

1. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L: Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 2001, 229:163-175
2. Wennbo H, Tornell J: The role of prolactin and growth hormone in breast cancer. Oncogene 2000, 19:1072-1076
3. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J: Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997, 100:2744-2751
4. Hennighausen L, Robinson GW: Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998, 12:449-455
5. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP: Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for mammary tumorigenesis. J Biol Chem 1998, 273:20448-20455
6. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJC, Pemberton P, Rafidi K, Ryan, K: RNA genetics of breast cancer: maspin as a paradigm. Cold Spring Harbor Sym Quant Biol 1994; LIX:537-546
7. Engelman JA, Zhang XL, Lisanti MP: Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1) Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 1999, 448:221-230
8. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, Pestell RG, Lisanti MP: Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 2000, 275:20717-20725
9. Park DS, Lee H, Riedel C, Hulit J, Scherer PE, Pestell RG, Lisanti MP: Prolactin negatively regulates caveolin-1 gene expression in the mammary gland during lactation, via a Ras-dependent mechanism. J Biol Chem 2001, 276:48389-48397
10. Lee SW, Reimer CL, Oh P, Campbel LDB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998, 16:1391-1397
11. Shridhar V, Sun QC, Miller OJ, Kalemkerian GP, Petros J, Smith DI: Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas. Oncogene 1997, 15:2727-2733
12. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI: A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 1998, 58:759-766
13. Engelman JA, Zhang XL, Galbiati F, Volonte D, Sotgia F, Pestell RG, Minetti C, Scherer PE, Okamoto T, Lisanti MP: Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer’s disease, and muscular dystrophy. Am J Hum Genet 1998, 63:1578-1587
14. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001, 61:2361-2364
15. Galbiati F, Volonté D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP: Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998, 17:6633-6648
16. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco P, Egeo A, Donati MA, Volonte D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, Zara F: Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998, 18:365-368
17. Scherer PE, Tang Z-L, Chun MC, Sargiacomo M, Lodish HF, Lisanti MP: Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 1995, 270:16395-16401
18. Scherer PE, Lederkremer GZ, Williams S, Fogliano M, Baldini G, Lodish HF: Cab45, a novel (Ca2+)-binding protein localized to the Golgi lumen. J Cell Biol 1996, 133:257-268
19. Sargiacomo M, Sudol M, Tang Z-L, Lisanti MP: Signal transducing molecules and GPI-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993, 122:789-807
20. Volonte D, Galbiati F, Lisanti MP: Visualization of caveolin-1, a caveolar marker protein, in living cells using green fluorescent protein (GFP) chimeras: the subcellular distribution of caveolin-1 is modulated by cell-cell contact. FEBS Lett 1999, 445:431-439
21. Sargiacomo M, Scherer PE, Tang ZL, Kubler E, Song KS, Sanders MC, Lisanti MP: Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA 1995, 92:9407-9411
22. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP: Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 1996, 93:131-135
23. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, Lisanti MP: Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 1997, 272:29337-29346
24. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, Lisanti MP: Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996, 271:2255-2261
25. Sargiacomo M, Scherer PE, Tang Z-L, Casanova JE, Lisanti MP: In vitro phosphorylation of caveolin-rich membrane domains: identification of an associated serine kinase activity as a casein kinase II-like enzyme. Oncogene 1994, 9:2589-2595
26. Smart E, Ying Y-S, Conrad P, Anderson RGW: Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol 1994, 127:1185-1197
27. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M: Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 1994, 126:111-126
28. Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Corley-Mastick C, Lodish HF: Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J Cell Biol 1994, 127:1233-1243
29. Lisanti MP, Tang Z-T, Scherer P, Sargiacomo M: Caveolae purification and GPI-linked protein sorting in polarized epithelia. Methods Enzymol 1995, 250:655-668
30. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP: Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 1995, 270:15693-15701
31. Schnitzer JE, Oh P, Jacobson BS, Dvorak AM: Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca2+-ATPase, and inositol triphosphate receptor. Proc Natl Acad Sci USA 1995, 92:1759-1763
32. Corley-Mastick C, Brady MJ, Saltiel AR: Insulin stimulates the tyrosine phosphorylation of caveolin. J Cell Biol 1995, 129:1523-1531
33. Robbins SM, Quintrell NA, Bishop MJ: Myryistoylation and differential palmitoylation of the HCK protein tyrosine kinases govern their attachment to membranes and association with caveolae. Mol Cell Biol 1995, 15:3507-3515
34. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, Lisanti MP: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138
35. Razani B, Lisanti MP: Caveolin-deficient mice: insights into caveolar function and human disease. J Clin Invest 2001, 108:1553-1561
36. Kurzchalia T, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, Simons K: VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 1992, 118:1003-1014
37. Dietzen DJ, Hastings WR, Lublin DM: Caveolin is palmitoylated on multiple cysteine residues: palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem 1995, 270:6838-6842
38. Schlegel A, Schwab R, Scherer PE, Lisanti MP: A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem 1999, 274:22660-22667
39. Schlegel A, Lisanti MP: A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem 2000, 275:21605-21617
40. Song KS, Li S, Okamoto T, Quilliam L, Sargiacomo M, Lisanti MP: Copurification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent free purification of caveolae membranes. J Biol Chem 1996, 271:9690-9697
41. Laxman R, Currie JL, Kurman RJ, Dudzinski M, Griffin CA: Cytogenetic profile of uterine sarcomas. Cancer 1993, 71:1283-1288
42. Xiu ZF: A preliminary cytogenetic study of uterine leiomyoma. Chung Hua Fu Chan Ko Tsa Chih 1993, 28:91-93
43. Achille A, Biasi MO, Zamboni G, Bogina G, Magalini AR, Pederzoli P, Perucho M, Scarpa A: Chromosome 7q allelic losses in pancreatic carcinoma. Cancer Res 1996, 56:3808-3813
44. Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R: Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992, 339:139-143
45. Huang H, Qian C, Jenkins RB, Smith DI: Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosom Cancer 1998, 21:152-159
46. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ: Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 1994, 54:6370-6373
47. Zenklusen JC, Bieche I, Lidereau R, Conti CJ: (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 1994, 91:12155-12158
48. Champeme MH, Bieche I, Beuzelin M, Lidereau R: Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosom Cancer 1995, 12:304-306
49. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick BG, Lieber MM, Thibadeau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995, 55:4114-4119
50. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M: Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosom Cancer 1998, 21:131-143
51. Zenklusen JC, Thompson JC, Klein-Szanto AJ, Conti CJ: Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res 1995, 55:1347-1350
52. Zenklusen JC, Weitzel JN, Ball HG, Conti CJ: Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene 1995, 11:359-363
53. Koike M, Takeuchi S, Yokota J, Park S, Hatta Y, Miller CW, Tsuruoka N, Koeffler HP: Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer. Genes Chromosom Cancer 1997, 19:1-5
54. Matsuura K, Shiga K, Yokoyama J, Saijo S, Miyagi T, Takasaka T: Loss of heterozygosity of chromosome 9p21 and 7q31 is correlated with high incidence of recurrent tumor in head and neck squamous cell carcinoma. Anticancer Res 1998, 18:453-458
55. Wang XL, Uzawa K, Miyakawa A, Shiiba M, Watanabe T, Sato T, Miya T, Yokoe H, Tanzawa H: Localization of a tumour-suppressor gene associated with human oral cancer on 7q31.1. Int J Cancer 1998, 75:671-674
56. Lin JC, Scherer SW, Tougas L, Traverso G, Tsui LC, Andrulis IL, Jothy S, Park M: Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene 1996, 13:2001-2008
57. Kerr J, Leary JA, Hurst T, Shih YC, Antalis TM, Friedlander M, Crawford E, Khoo SK, Ward B, Chenevix-Trench G: Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Oncogene 1996, 13:1815-1818
58. Engelman JA, Zhang XL, Galbiati F, Lisanti MP: Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett 1998, 429:330-336
59. Engelman JA, Zhang XL, Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998, 436:403-410
60. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995, 92:1381-1385
61. Engelman JA, Wycoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997, 272:16374-16381
62. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 2000, 39:13916-13924
63. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, lavarone A, Lisanti MP: Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 2001, 40:3354-3362
64. Fiucci G, Ravid D, Reich R, Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002, 21:2365-2375
65. Fra AM, Mastroianni N, Mancini M, Pasqualetto E, Sitia R: Human caveolin-1 and caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors. Genomics 1999, 56:355-356
66. Bender FC, Reymond MA, Bron C, Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000, 60:5870-5878
67. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S: Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 2000, 19:4754-4763
68. Morgan MB, Stevens GL, Tannenbaum M, Salup R: Expression of the caveolins in dermal vascular tumors. J Cutan Pathol 2001, 28:24-28
69. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 2001, 158:833-839
70. Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C: Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001, 159:1635-1643
71. Pflug BR, Reiter RE, Nelson JB: Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 1999, 40:269-273
72. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR: Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 2001, 46:249-256